Chronic Ocular Graft- Versus-Host Disease Market

Author: Reports and Insights

Increased Penetration of Stem Cell Therapy is expected to Push the Market for Chronic Ocular graft-versus-host Disease

 

Reports and Insights (R&I) has published a new report titled, Chronic Ocular Graft-versus-host Disease Market: Opportunity Analysis and Future Assessment 2020 to 2028

Global Chronic Ocular Graft-versus-host Disease Market, by Treatment (Immunosuppressant, steroids, autologous serum eye drops, amniotic membrane transplantation), By Distribution Channel (Hospitals pharmacies, Clinics, Retail Pharmacy, & Drug Stores), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, & Africa) is expected to grow at a significant CAGR for the period between 2020 and 2028.

As per the report, the rapidly growing prevalence of graft versus host disease and the increasing number of stem cell transplantation procedures are identified as major factors driving the growth of the chronic ocular graft versus host disease market. Ocular graft versus host disease (GVHD) occurs in patients who have undergone allogeneic hematological stem cell transplantation. Approximately 40-90% of patients with chronic graft-versus-host disease develop ocular symptoms. The chronic condition develops in patients especially because of non-compliance to the immunosuppressant treatment. Manifestations of chronic ocular graft-versus-host disease are keratoconjunctivitis sicca, corneal ulceration, anterior uveitis, bilateral marginal keratitis.

Ocular graft-versus-host disease occurs when donor lymphocytes attack host histocompatibility antigen. Symptoms of ocular graft-versus-host disease include dry eye, foreign body sensation, redness, irritation, etc. Ocular GVHD has the potential to lead to severe ocular problems, impair quality of life, and restrict daily activities. Growing penetration of stem cell therapies increases the chances of the development of chronic ocular graft versus host disease.

Furthermore, Reports and Insights (R&I) Study identifies that in 25% to 70% of patients ocular graft-versus-host disease is responsible for non-relapse morbidity and mortality. Hematopoietic stem cell transplantation (SCT), including bone marrow transplantation (BMT), peripheral blood stem cell transplantation, and cord blood transplantation is a routine procedure and it offers a potential cure for life-threatening diseases such as aplastic anemia, hematological malignancies, lysosomal storage disorders, etc. Ocular graft-versus-host disease is one of the major complications of allogeneic stem cell transplant. The first-line treatment for chronic ocular graft-versus-host disease includes immunosuppressant and topical steroids.

Immunosuppressant treatment for the chronic ocular graft-versus-host disease is methotrexate, cyclosporine, and anti-lymphocyte antibodies. Topical steroids approved for the treatment of chronic inflammation and maintaining mucosal integrity. The latest approval of generic loteprednol etabonate is expected to push the market growth. Further new treatment options being developed such as amniotic membrane transplantation, autologous serum eye drops are expected to be launched in the market in the next few years. The amniotic membrane is rich in cytokines, growth factors, and protease inhibitors and serves as a biological bandage that suppresses inflammation and promotes epithelialization. Amniotic membrane transplantation can avoid systemic immunosuppression and also decreases the recurrence of the primary condition.

R&I Study identifies some of the key players operating in the chronic ocular graft-versus-host disease market globally are Bauch and Lomb, Akorn Inc., Apotex Corporation, Pfizer Inc., Par Pharmaceutical, Accord Healthcare Limited, Sandoz (Novartis), Medexus Inc., Nordic Group Bv, Actavis Pharma, Allergan Inc., etc.

About Reports and Insights (R&I):

Reports and Insights (R&I) is committed to provide deep insights that serve as creative tool for the client that enables it to perform confidently in the market. At R&I we adhere to the client needs and regularly ponder to bring out more valuable and real outcomes for our customers. We are equipped with strategically enhanced group of researchers and analysts that redefines and stabilizes the business polarity in different categorical dimensions of the market.

Contact Us:

Reports and Insights (R&I)

Tel: +1-(281)-619-8646

For Sales Queries: sales@reportsandinsights.com

For New Topics and Other Info: info@reportsandinsights.com